Relmada Therapeutics, Inc. Common Stock
Symbol: RLMD (NASDAQ)
1.54
▼ (-6.97%) -0.115
Company Description:
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Key Stats
- Today's Open: $1.65
- Today's High: $1.69
- Today's Low: $1.51
- Today's Volume: 317.47K
- Yesterday Close: $1.65
- Yesterday High: $1.68
- Yesterday Low: $1.52
- Yesterday Volume: 427.95K
- Last Min Volume: 212
- Last Min High: $1.535
- Last Min Low: $1.535
- Last Min VWAP: $1.535
Company Profile
- Name: Relmada Therapeutics, Inc. Common Stock
- Website: https://www.relmada.com
- Listed Date: 2014-03-03
- Location: CORAL GABLES, FL
- Market Status: Active
- CIK Number: 0001553643
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $50.78M
- Round Lot: 100
- Outstanding Shares: 33.19M
- Asset Type: CS
RECENT FILINGS FOR RLMD
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-17 | 8-K | View |
| 2025-09-16 | 8-K | View |
| 2025-09-10 | 8-K | View |
| 2025-09-02 | 8-K | View |
| 2025-08-28 | 4 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-07 | 8-K | View |
| 2025-08-07 | 10-Q | View |
| 2025-07-23 | 8-K | View |
| 2025-07-10 | 8-K | View |
| 2025-06-30 | 4 | View |
| 2025-06-30 | 4 | View |
| 2025-06-30 | 4 | View |
| 2025-06-30 | 4 | View |
| 2025-06-30 | 4 | View |
| 2025-06-30 | 4 | View |
| 2025-06-30 | 4 | View |
| 2025-06-18 | 8-K | View |
| 2025-06-13 | S-8 | View |
| 2025-05-27 | 8-K | View |
Latest News on RLMD